SCHEMBL3299285

SCHEMBL3299285

CCCCC(O)C(O)(O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.43
MAPK1 P28482 1/20 0.43
GPR84 Q9NQS5 7/20 0.42
FFAR1 O14842 2/20 0.42
HSPD1 P10809 1/20 0.40
BLM P54132 1/20 0.40
HSPE1 P61604 1/20 0.40
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
CA1 P00915 1/20 0.38
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148025 0.92 GPR84 (0.53) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL18322324 0.92 GPR84 (0.53) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL325989 0.92 GPR84 (0.53) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL9297272 0.92 GPR84 (0.53) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL6686309 0.90 GPR84 (0.52) GPR84FFAR1HSPD1BLMHSPE1
Ammonia Solution, Strong SCHEMBL10519337 0.90 GPR84 (0.52) GPR84FFAR1HSPD1BLMHSPE1
Ethylene Glycol SCHEMBL26926887 0.87 GPR84 (0.48) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL2065137 0.86 CHRM1 (0.42) GPR84FFAR1HSPD1BLMHSPE1
Glycerin SCHEMBL158648 0.85 GPR84 (0.49) GPR84FFAR1HSPD1BLMHSPE1
SCHEMBL28356481 0.85 GPR84 (0.47) GPR84FFAR1HSPD1BLMHSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120277311-A1 LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS THE BRIGHAM AND WOMEN'S HOSPITAL , INC. 2012-11-01 US disclosed
US-7825271-B2 Lipoxin compounds and their use in treating cell proliferative disorders THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-11-02 US disclosed
US-7741369-B2 Lipoxin compounds and their use in treating cell proliferative disorders THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2010-06-22 US disclosed
US-20090270498-A1 Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2009-10-29 US disclosed
US-20090258945-A1 Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2009-10-15 US disclosed
EP-2107050-A1 Lipoxin compounds The Brigham and Women's Hospital, Inc. (US) 2009-10-07 EP disclosed
EP-2058293-A1 Lipoxin compounds and their use in treating cell proliferative disorders The Brigham & Women's Hospital, Inc. (US) 2009-05-13 EP disclosed
EP-0703897-B1 LIPOXIN COMPOUNDS WITH PROLONGED HALF-LIFE BRIGHAM & WOMENS HOSPITAL (US) 2008-08-20 EP disclosed
EP-1201639-B1 Lipoxin compounds and their use in treating cell proliferative disorders BRIGHAM & WOMENS HOSPITAL (US) 2008-08-13 EP disclosed
US-7294728-B2 Lipoxin compounds and their use in treating cell proliferative disorders SERHAN CHARLES N 2007-11-13 US disclosed
US-20020010351-A1 Lipoxin compounds and their use in treating cell proliferative disorders SERHAN CHARLES N (US) 2002-01-24 US disclosed
US-6316648-B1 PURIFIED 5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID; ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2001-11-13 US disclosed
US-20010031882-A1 Lipoxin compounds and their use in treating cell proliferative disorders SERHAN CHARLES N (US) 2001-10-18 US disclosed
US-6048897-A ALSO ANTICARCINOGENIC OR ANTITUMOR AGENTS BRIGHAM AND WOMEN'S HOSPITAL (US) 2000-04-11 US disclosed
EP-0927150-A1 LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS BRIGHAM & WOMEN'S HOSPITAL (US) 1999-07-07 EP disclosed
WO-1998011049-A1 LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS BRIGHAM & WOMEN'S HOSPITAL (US) 1998-03-19 WO disclosed
US-5648512-A Lipoxin compounds BRIGHAM & WOMENS HOSPITAL (US) 1997-07-15 US disclosed
EP-0703897-A1 LIPOXIN COMPOUNDS BRIGHAM & WOMEN'S HOSPITAL (US) 1996-04-03 EP disclosed
US-5441951-A Lipoxin compounds BRIGHAM & WOMEN'S HOSPITAL (US) 1995-08-15 US disclosed
WO-1994029262-A1 LIPOXIN COMPOUNDS BRIGHAM & WOMEN'S HOSPITAL (US) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258945-A1 Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders ALOX15, ALOX12, ALOX15B CA2 4848/4885MAPK1 2822/4885GPR84 3209/4885
US-20020010351-A1 Lipoxin compounds and their use in treating cell proliferative disorders ALOX15, ALOX12, ALOX15B CA2 4848/4885MAPK1 2822/4885GPR84 3209/4885
US-20090270498-A1 Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders ALOX15, ALOX12, ALOX15B CA2 4848/4885MAPK1 2822/4885GPR84 3209/4885
US-20010031882-A1 Lipoxin compounds and their use in treating cell proliferative disorders ALOX15, ALOX12, ALOX15B CA2 4848/4885MAPK1 2822/4885GPR84 3209/4885
US-20120277311-A1 LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS ALOX15, ALOX12, ALOX15B CA2 4848/4885MAPK1 2822/4885GPR84 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.